Description
Product Overview: Cagrilintide
Cagrilintide is a novel, long-acting synthetic acylated analog of the pancreatic peptide hormone amylin. Naturally co-secreted with insulin by beta cells, amylin plays a primary role in mealtime satiety and postprandial glucose regulation. Engineered with a fatty acid side-chain that enables reversible binding to serum albumin, Cagrilintide exhibits a significantly prolonged plasma half-life, providing an advanced research model for non-incretin neuro-metabolic signaling, appetite control, and combination metabolic therapies.
Primary Research Applications & Reasons for Study
- Central Satiety Signaling: Activating central amylin (AMY) and calcitonin (CTR) receptor complexes in the brainstem to signal fullness and suppress feed intake.
- Gastric Emptying Delay: Prolonging gastrointestinal transit time to smooth postprandial glucose spikes and extend nutrient saturation signals.
- Dual-Targeting Synergies: Evaluating co-administration with GLP-1 receptor agonists (e.g., Semaglutide or Tirzepatide) to produce additive metabolic and body-weight-reduction outcomes.
- Glucagon Suppression: Decreasing post-meal glucagon secretion to limit hepatic glucose production during fed states.
Expected Research Results & Timeline Metrics
- Phase 1 / Days 1–3
Acute Satiety Response: Rapid, measurable reductions in acute food intake metrics and pronounced slowing of liquid/solid gastric emptying rates. - Phase 2 / Weeks 1–3
Weight & Intake Reduction: Statistically significant drops in cumulative food consumption and steady reductions in overall body weight parameters in experimental models. - Phase 3 / Weeks 4–8+
Synergistic Potentiation: Enhanced, multi-pathway weight loss and total adipose mass reduction when evaluated alongside GLP-1 analogs, alongside stabilized postprandial glycemic control curves.
Key Research Benefits
- Novel Non-GLP-1 Weight Management: Offers an alternative neuro-metabolic target for studies addressing GLP-1 non-responders or plateaus.
- Extensive Plasma Half-Life: Structural acylation enables binding to serum albumin, allowing sustained receptor activation in long-term study protocols.
- Additive Weight Loss Dynamics: Demonstrates superior efficacy in multi-agonist combination assays compared to single-agent therapies.
- Glycemic Stabilization: Suppresses excess glucagon without increasing hypoglycemia risk in normoglycemic models.
THIS PRODUCT IS INTENDED SOLELY FOR IN VITRO LABORATORY RESEARCH AND EXPERIMENTAL PURPOSES. It is strictly prohibited for human consumption, clinical trials, therapeutic administration, cosmetic use, or veterinary application. This product is not an FDA-approved drug, medical food, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease, illness, or medical condition. Any handling, reconstitution, or experimentation involving this chemical compound must be conducted strictly by qualified, trained laboratory professionals utilizing appropriate containment and personal protective equipment in accordance with scientific biosafety standards. Buyers and users assume full liability for compliance with local, state, and federal laws regarding the handling and possession of research peptides.